RxDoctor Payments Data

Robert Rosen, DO

Dermatology · Toms River, NJNPI 1275512840

Payments from drug & device makers

$891in general payments, 2019–2025

Across 32 payments — averaging $27.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$296
  • Sun Pharmaceutical Industries Inc.$217
  • AbbVie$171
  • Sanofi$34
  • LEO Pharma Inc.$32
  • Biofrontera Inc.$27
  • plus $115 from 8 others

What the payments were for

  • Food & beverage$50857%
  • Education$38343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$891 in reported general payments places this provider in the 30th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$690,654
Medicare patients
1,547
Services billed
6,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast50$274,096
Skyrizi PenRisankizumab-Rzaa11$221,515
Dupixent PenDupilumab26$159,426
Dupixent SyringeDupilumab18$103,858
Humira(Cf) PenAdalimumab14$93,506
Taltz AutoinjectorIxekizumab13$87,101
Tacrolimus52$7,304
Fluorouracil117$6,771
Ketoconazole221$4,176
Clobetasol Propionate85$4,143
Pimecrolimus19$3,340
Calcipotriene19$3,335
Triamcinolone Acetonide323$2,835
Fluocinolone Acetonide65$2,374
ValacyclovirValacyclovir Hcl60$2,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$19$274,09650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →